Literature DB >> 29208658

Unbiased Approach to Counteract Upward Drift in Cerebrospinal Fluid Amyloid-β 1-42 Analysis Results.

Betty M Tijms1, Eline A J Willemse2, Marissa D Zwan3, Sandra D Mulder3, Pieter Jelle Visser3,4, Bart N M van Berckel5, Wiesje M van der Flier3,6, Philip Scheltens3, Charlotte E Teunissen2.   

Abstract

BACKGROUND: Low cerebrospinal fluid (CSF) amyloid-β 1-42 (Aβ 1-42) concentrations indicate amyloid plaque accumulation in the brain, a pathological hallmark of Alzheimer disease (AD). Innotest assay values of Aβ 1-42 have gradually increased over the past 2 decades, which might lead to misclassification of AD when a single cutpoint for abnormality is used. We propose an unbiased approach to statistically correct for drift.
METHODS: We determined year-specific cutpoints with Gaussian mixture modeling, based on the cross-section of bimodal distributions of Aβ 1-42 concentrations in 4397 memory clinic patients. This allowed us to realign year-specific cutpoints as an unbiased method to remove drift from the data. Sensitivity and specificity to detect AD dementia were compared between corrected and uncorrected values.
RESULTS: Aβ 1-42 values increased 22 pg/mL annually, and this could not be explained by changes in cohort composition. Our approach removed time dependencies [β (SE) = 0.07 (0.59); P = 0.91]. Statistically correcting for drift improved the sensitivity to detect AD dementia to 0.90 (95% CI, 0.89-0.92) from at least 0.66 (95% CI, 0.64-0.69) based on uncorrected data. Specificity became lower (0.69; 95% CI, 0.67-0.70) vs at most 0.80 (95% CI, 0.79-0.82) for uncorrected data.
CONCLUSIONS: This approach may also be useful to standardize Aβ 1-42 CSF concentrations across different centers and/or platforms, and to optimize use of CSF biomarker data collected over a long period.
© 2017 American Association for Clinical Chemistry.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 29208658     DOI: 10.1373/clinchem.2017.281055

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  54 in total

1.  Latent atrophy factors related to phenotypical variants of posterior cortical atrophy.

Authors:  Colin Groot; B T Thomas Yeo; Jacob W Vogel; Xiuming Zhang; Nanbo Sun; Elizabeth C Mormino; Yolande A L Pijnenburg; Bruce L Miller; Howard J Rosen; Renaud La Joie; Frederik Barkhof; Philip Scheltens; Wiesje M van der Flier; Gil D Rabinovici; Rik Ossenkoppele
Journal:  Neurology       Date:  2020-07-16       Impact factor: 9.910

2.  P-tau subgroups in AD relate to distinct amyloid production and synaptic integrity profiles.

Authors:  Kirsten E J Wesenhagen; Betty M Tijms; Lynn Boonkamp; Patty L Hoede; Julie Goossens; Nele Dewit; Philip Scheltens; Eugeen Vanmechelen; Pieter Jelle Visser; Charlotte E Teunissen
Journal:  Alzheimers Res Ther       Date:  2022-07-15       Impact factor: 8.823

3.  Establishment of combined diagnostic models of Alzheimer's disease in a Chinese cohort: the Chongqing Ageing & Dementia Study (CADS).

Authors:  Dong-Yu Fan; Jie-Ming Jian; Shan Huang; Wei-Wei Li; Ying-Ying Shen; Zhen Wang; Gui-Hua Zeng; Xu Yi; Wang-Sheng Jin; Yu-Hui Liu; Fan Zeng; Xian-Le Bu; Li-Yong Chen; Qing-Xiang Mao; Zhi-Qiang Xu; Jin-Tai Yu; Jun Wang; Yan-Jiang Wang
Journal:  Transl Psychiatry       Date:  2022-06-16       Impact factor: 7.989

4.  Identifying Sensitive Measures of Cognitive Decline at Different Clinical Stages of Alzheimer's Disease.

Authors:  Roos J Jutten; Sietske A M Sikkes; Rebecca E Amariglio; Rachel F Buckley; Michael J Properzi; Gad A Marshall; Dorene M Rentz; Keith A Johnson; Charlotte E Teunissen; Bart N M Van Berckel; Wiesje M Van der Flier; Philip Scheltens; Reisa A Sperling; Kathryn V Papp
Journal:  J Int Neuropsychol Soc       Date:  2020-10-13       Impact factor: 2.892

5.  Kinetics and 28-day test-retest repeatability and reproducibility of [11C]UCB-J PET brain imaging.

Authors:  Hayel Tuncel; Ronald Boellaard; Emma M Coomans; Erik Fj de Vries; Andor Wjm Glaudemans; Paula Kopschina Feltes; David V García; Sander Cj Verfaillie; Emma E Wolters; Steven P Sweeney; J Michael Ryan; Magnus Ivarsson; Berkley A Lynch; Patrick Schober; Philip Scheltens; Robert C Schuit; Albert D Windhorst; Peter P De Deyn; Bart Nm van Berckel; Sandeep Sv Golla
Journal:  J Cereb Blood Flow Metab       Date:  2020-10-08       Impact factor: 6.200

6.  Differential patterns of gray matter volumes and associated gene expression profiles in cognitively-defined Alzheimer's disease subgroups.

Authors:  Colin Groot; Michel J Grothe; Shubhabrata Mukherjee; Irina Jelistratova; Iris Jansen; Anna Catharina van Loenhoud; Shannon L Risacher; Andrew J Saykin; Christine L Mac Donald; Jesse Mez; Emily H Trittschuh; Gregor Gryglewski; Rupert Lanzenberger; Yolande A L Pijnenburg; Frederik Barkhof; Philip Scheltens; Wiesje M van der Flier; Paul K Crane; Rik Ossenkoppele
Journal:  Neuroimage Clin       Date:  2021-04-03       Impact factor: 4.881

7.  The predictive value of normal EEGs in dementia due to Alzheimer's disease.

Authors:  Casper T Briels; Cornelis J Stam; Philip Scheltens; Alida A Gouw
Journal:  Ann Clin Transl Neurol       Date:  2021-04-09       Impact factor: 4.511

8.  Highly specific and ultrasensitive plasma test detects Abeta(1-42) and Abeta(1-40) in Alzheimer's disease.

Authors:  Elisabeth H Thijssen; Inge M W Verberk; Jeroen Vanbrabant; Anne Koelewijn; Hans Heijst; Philip Scheltens; Wiesje van der Flier; Hugo Vanderstichele; Erik Stoops; Charlotte E Teunissen
Journal:  Sci Rep       Date:  2021-05-06       Impact factor: 4.379

9.  Relevance of Aβ42/40 Ratio for Detection of Alzheimer Disease Pathology in Clinical Routine: The PLMR Scale.

Authors:  Sylvain Lehmann; Constance Delaby; Guilaine Boursier; Cindy Catteau; Nelly Ginestet; Laurent Tiers; Aleksandra Maceski; Sophie Navucet; Claire Paquet; Julien Dumurgier; Eugeen Vanmechelen; Hugo Vanderstichele; Audrey Gabelle
Journal:  Front Aging Neurosci       Date:  2018-05-28       Impact factor: 5.750

10.  Saliva Neurofilament Light Chain Is Not a Diagnostic Biomarker for Neurodegeneration in a Mixed Memory Clinic Population.

Authors:  Helena Sophia Gleerup; Federica Sanna; Peter Høgh; Joel Simrén; Kaj Blennow; Henrik Zetterberg; Steen Gregers Hasselbalch; Nicholas J Ashton; Anja Hviid Simonsen
Journal:  Front Aging Neurosci       Date:  2021-05-10       Impact factor: 5.750

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.